JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M601570200 on May 25, 2006 Originally published In Press as doi:10.1074/jbc.M601570200 on May 25, 2006

J. Biol. Chem., Vol. 281, Issue 30, 20851-20864, July 28, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/30/20851    most recent
M601570200v2
M601570200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by González, L.
Right arrow Articles by Martín-Pérez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González, L.
Right arrow Articles by Martín-Pérez, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Role of c-Src in Human MCF7 Breast Cancer Cell Tumorigenesis*Formula

Lorena González{ddagger}1, María Teresa Agulló-Ortuño{ddagger}2, José Manuel García-Martínez{ddagger}3, Annarica Calcabrini§, Carlos Gamallo{ddagger}, José Palacios4, Ana Aranda{ddagger}, and Jorge Martín-Pérez{ddagger}5

From the {ddagger}Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Arturo Duperier 4, 28029 Madrid, Spain, the §Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy, and the Centro Nacional de Investigaciones Oncológicas, Melchor Fernández Almagro 3, 28029 Madrid, Spain

To study the role of c-Src in breast cancer tumorigenesis, we generated a cell line derived from MCF7 carrying an inducible dominant negative c-Src (c-SrcDN: K295M/Y527F) under tetracycline control (Tet-On system). c-SrcDN expression caused phenotypic changes, relocation of c-Src, Fak, and paxillin, and loss of correct actin fiber assembly. These alterations were coupled to increased Fak-Tyr397 autophosphorylation and to inhibition of Fak-Tyr925, p130CAS, and paxillin phosphorylation. An increased association of total Src with Fak and a decreased interaction of p130CAS and p85-PI3K with Fak were also observed. SrcDN inhibited cell attachment, spreading, and migration. Serum and EGF-induced stimulation of cell proliferation and Akt phosphorylation were also significantly reduced by SrcDN, whereas p27Kip1 expression was increased. Consistently, silencing c-Src expression by siRNA in MCF7 cells significantly reduced cell migration, attachment, spreading and proliferation. Inoculation of MCF7 cells carrying inducible SrcDN to nude mice generated tumors. However, doxycycline administration to mice significantly reduced tumorigenesis, and when doxycycline treatment was installed after tumor development, a significant tumor regression was observed. In both situations, inhibition of tumorigenesis was associated with decreased Ki67 staining and increased apoptosis in tumors. These data undoubtedly demonstrate the relevance of the Src/Fak complex in breast cancer tumorigenesis.


Received for publication, February 17, 2006

* This work was supported by Grants from Ministerio de Educación y Ciencia (SAF2003-02188) and Fondo de Investigaciones Sanitarias (01/1316, 04/0682, and 03C03/10). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental materials.

1 Supported by a fellowship from Fundación Carolina and by Grant FIS 03C03/10.

2 Supported by the FIS 03C03/10 Grant.

3 Supported by a fellowship from FIS and by Grant SAF2003-02188.

4 Member of GEICAM.

5 Member of GEICAM. To whom correspondence should be addressed. Tel.: 34915854416; Fax: 34915854401; E-mail: jmartin{at}iib.uam.es.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
R. S. Finn
Targeting Src in breast cancer
Ann. Onc., May 16, 2008; (2008) mdn291v1.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Vultur, R. Buettner, C. Kowolik, W. Liang, D. Smith, F. Boschelli, and R. Jove
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1185 - 1194.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Baumgartner, G. Radziwill, M. Lorger, A. Weiss, and K. Moelling
c-Src-Mediated Epithelial Cell Migration and Invasion Regulated by PDZ Binding Site
Mol. Cell. Biol., January 15, 2008; 28(2): 642 - 655.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
O. Norkina, A. Dolganiuc, T. Shapiro, K. Kodys, P. Mandrekar, and G. Szabo
Acute alcohol activates STAT3, AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes
J. Leukoc. Biol., September 1, 2007; 82(3): 752 - 762.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
E. Matteucci, E. Ridolfi, P. Maroni, P. Bendinelli, and M. A. Desiderio
c-Src/Histone Deacetylase 3 Interaction Is Crucial for Hepatocyte Growth Factor Dependent Decrease of CXCR4 Expression in Highly Invasive Breast Tumor Cells
Mol. Cancer Res., August 1, 2007; 5(8): 833 - 845.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
R. P. Carnevale, C. J. Proietti, M. Salatino, A. Urtreger, G. Peluffo, D. P. Edwards, V. Boonyaratanakornkit, E. H. Charreau, E. B. de Kier Joffe, R. Schillaci, et al.
Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways
Mol. Endocrinol., June 1, 2007; 21(6): 1335 - 1358.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.